Kura Oncology reports $5.8 million revenue in Q1 2026
Kura Oncology reported $5.8 million in net product revenue for Q1 2026 from Comzifty sales, with a net loss of $73.3 million. R&D expenses increased to $65.3 million, while SG&A expenses rose to $31.6 million. Cash reserves stood at $580.8 million as of March 31, 2026. The company maintained its collaboration revenue guidance and reported strong enrollment in its COMET-017 trials.
*this image is generated using AI for illustrative purposes only.
Kura Oncology reported $5.8 million in net product revenue for the first quarter of 2026, marking the first full quarter of commercial sales for Comzifty. The company recorded a net loss of $73.3 million for the period, compared to a net loss of $57.4 million in the prior year. Management highlighted that the early commercial performance exceeded expectations and positions the company to define leadership in the Menin inhibitor class over the next 12 to 24 months.
Financial Performance
The revenue generation was accompanied by increased operational expenses as the company advanced its clinical programs and commercial infrastructure. Research and development expenses rose to $65.3 million, up from $56 million in the first quarter of 2025. Selling, general, and administrative expenses increased to $31.6 million, compared to $22.8 million in the same period last year, driven by the commercial launch of Comzifty.
Collaboration revenue for the quarter was $12.5 million, a decrease from $14.1 million in the prior year. The company maintained its guidance for collaboration revenue, expecting it to range between $45 million and $55 million in 2026, $90 million to $110 million in 2027, and $90 million to $110 million in 2028.
Balance Sheet and Guidance
As of March 31, 2026, Kura Oncology held cash, cash equivalents, and short-term investments totaling $580.8 million. This figure compares to $667.2 million as of December 31, 2025. The company stated that its current cash position, combined with anticipated payments of $180 million under a collaboration agreement, is sufficient to fund operations through the first top-line Phase 3 results from the COMET-017 trial anticipated in 2027.
| Financial Metric | Q1 2026 ($) | Q1 2025 ($) |
|---|---|---|
| Net Product Revenue | 5.8 million | None |
| Collaboration Revenue | 12.5 million | 14.1 million |
| Research & Development Expenses | 65.3 million | 56 million |
| Selling, General & Administrative Expenses | 31.6 million | 22.8 million |
| Net Loss | 73.3 million | 57.4 million |
| Cash, Cash Equivalents & Short-term Investments | 580.8 million | 667.2 million* |
*As of December 31, 2025.
Operational and Clinical Updates
Commercial execution for Comzifty included 85 new patient starts and nearly 160 total prescriptions across approximately 60 activated accounts. Management noted strong enrollment in the COMET-017 trials, which are progressing ahead of plan. The company expects to present updated data from the Ziftomenib and 7+3 combination at the EHA meeting in June, as well as preliminary data from the Ziftomenib and gilteritinib combination in the second half of the year.
What specific factors will drive the projected increase in collaboration revenue from 2026 to 2027?
How will the company manage the widening net loss as it scales commercial operations and advances clinical trials?
What are the key milestones for Comzifty's market penetration over the next 12 to 24 months to achieve leadership in the Menin inhibitor class?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
